PARIS--(BUSINESS WIRE)--Regulatory News: Exonhit (Paris:ALEHT) today announced that it has entered into a research agreement with Pfizer Inc. for the identification of new Alzheimer’s disease (AD) biomarkers using Exonhit’s Genome-Wide SpliceArray™ (GWSA) platform.
